Physician profile
Muhammad Umar Khan
NPI 1689771099
$2,870.53
in general payments reported to CMS, 2019-2025
22 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $36.34 · 2021: $182 · 2022: $103 · 2023: $1,072 · 2024: $403 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333 · Travel and Lodging: $748 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.28 |
| Travel and Lodging | $748.30 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $748.30 | 2023 | Prostep |
| Astrazeneca Pharmaceuticals LP | $283.95 | 2019-2024 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $248.09 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $235.00 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $205.77 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $195.48 | 2019-2020 | |
| Axsome Therapeutics, INC. | $174.38 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $160.61 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $130.04 | 2023-2024 | Austedo Xr |
| Biogen, INC. | $90.86 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.42 | 2025 | Caplyta |
| Lundbeck LLC | $51.87 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $49.53 | 2024-2025 | Gemtesa |
| Shionogi INC | $43.71 | 2024-2025 | Fetroja |
| Biohaven Pharmaceuticals, INC. | $35.87 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35.61 | 2024-2025 | Perclose Prostyle, Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $22.88 | 2023 | Nuzyra |
| Exact Sciences Corporation | $20.39 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $19.81 | 2021 | |
| Boston Scientific Corporation | $19.46 | 2021 | |
| Novo Nordisk INC | $17.79 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $15.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.